schema:articleBody
| - Features Editors: Paris: Kate Millar +33 1 4041 4636 Hong Kong: Sean Gleeson +852 2829 6249 In the early months of the pandemic, US pharmaceutical giant Pfizer and a smaller German biotech firm, BioNTech, teamed up to develop a vaccine against Covid-19. One year on, AFP looks at the ambitious goal that paid off, visits a BioNTech vaccine production plant in Germany and a French warehouse for the arrival of the highly awaited doses. We are offering the following items: + The Pfizer/BioNTech vaccine bet that paid off + Inside Covid vaccine production at BioNTech's new plant + At a French warehouse, the logistics of racing out vaccines Health-virus-vaccines-Pfizer-BioNTech,BACKGROUND PARIS With a strategic alliance, 24-hour production and a bit of luck, Pfizer and BioNTech were able to roll out their Covid vaccine at a brisk pace and relatively free of controversy. 900 words by Julien Dury Health-virus-Germany-vaccine,FOCUS MARBURG, Germany Decontamination chambers, tight-fitting protective suits, a controlled atmosphere: vigilance is the order of the day when making Covid-19 vaccines at the new BioNTech plant in Marburg, Germany. 600 words by Yann Schreiber. Pictures by Thomas Lohnes. Video by Raphaelle Logerot Health-virus-France-vaccines-delivery,SCENE PARIS In an unmarked warehouse on the outskirts of Paris, a precious cargo emerges from the icy cold mist: nearly 10,000 doses of the Pfizer-BioNTech vaccine have just been delivered. 550 words by Gabriel Bourovitch. Pictures by Joel Saget. Video Viken Kantarci afp
|